These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16405225)

  • 21. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
    Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
    Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost effectiveness and cost-savings opportunities associated with human growth hormone.
    Manag Care Interface; 2005; Suppl():14-5. PubMed ID: 16268200
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA hears opinions on need for regulation of pharmacoeconomic information.
    Am J Health Syst Pharm; 1996 Mar; 53(6):604, 607. PubMed ID: 8800960
    [No Abstract]   [Full Text] [Related]  

  • 24. How can pharmacoeconomics be more useful?
    Kozma CM
    Manag Care Interface; 2005 May; 18(5):25-6. PubMed ID: 15941186
    [No Abstract]   [Full Text] [Related]  

  • 25. Comment: substantiation in pharmacoeconomic evaluations.
    Langley PC
    Ann Pharmacother; 1995 Sep; 29(9):942-3. PubMed ID: 8547756
    [No Abstract]   [Full Text] [Related]  

  • 26. The focus on true value in the health care system.
    Giaquinta D
    Manag Care Interface; 2007 Apr; 20(4):40-1. PubMed ID: 17474329
    [No Abstract]   [Full Text] [Related]  

  • 27. Assessment of the prevalence and costs of osteoporosis treatment options in a real-world setting.
    Brixner D
    Am J Manag Care; 2006 May; 12(7 Suppl):S191-8. PubMed ID: 16686588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Realizing the pharmacoeconomic benefit of clinical pharmacy.
    Kaboli P
    Am J Health Syst Pharm; 2008 Jun; 65(12):1123. PubMed ID: 18541681
    [No Abstract]   [Full Text] [Related]  

  • 29. Economic model shows savings through finer dosing increments.
    Bazalo G
    Manag Care Interface; 2005; Suppl():10-1. PubMed ID: 16268198
    [No Abstract]   [Full Text] [Related]  

  • 30. Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States.
    Jhaveri M; Seal B; Pollack M; Wertz D
    Curr Med Res Opin; 2007 Jun; 23(6):1431-43. PubMed ID: 17559740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effective psoriasis treatment may demand creative coverage rules.
    Morrow T
    Manag Care; 2006 May; 15(5):61-3. PubMed ID: 16749523
    [No Abstract]   [Full Text] [Related]  

  • 32. Does cost-effectiveness play a role in clinical trials?
    Steele T; Pawaskar M; Balkrishnan R; Fleischer A; Feldman SR
    Dermatol Ther; 2007; 20(2):110-9. PubMed ID: 17537139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoeconomic modelling in schizophrenia. Trap or support for decision makers?
    Hansen K; Lançon C; Toumi M
    Eur J Health Econ; 2006 Mar; 7(1):19-29. PubMed ID: 16528579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacoeconomics and macular degeneration.
    Brown GC; Brown MM; Brown H; Godshalk AN
    Curr Opin Ophthalmol; 2007 May; 18(3):206-11. PubMed ID: 17435427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bacterial meningitis vaccination failure].
    Levy C; Bingen E; De La Rocque F; Varon E; Alonso JM; Dabernat H; Aujard Y; Cohen R;
    Arch Pediatr; 2008 Jun; 15(5):545-7. PubMed ID: 18582667
    [No Abstract]   [Full Text] [Related]  

  • 36. PHARMAC's updated guidelines for cost-effectiveness analyses, with new discount rate.
    Grocott R; Metcalfe S
    N Z Med J; 2007 Jul; 120(1258):U2641. PubMed ID: 17653257
    [No Abstract]   [Full Text] [Related]  

  • 37. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
    Mullins CD; Subedi PR; Healey PJ; Sanchez RJ
    Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacoeconomics in the era of individualized medicine.
    Waldman SA; Terzic A
    Clin Pharmacol Ther; 2008 Aug; 84(2):179-82. PubMed ID: 18679176
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
    Piskur P; Sonc M; Cufer T; Borstnar S; Mrhar A
    Anticancer Drugs; 2006 Jul; 17(6):719-24. PubMed ID: 16917219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on utilities and cost-utility analyses.
    Hollands H; Sharma S
    Curr Opin Ophthalmol; 2006 Jun; 17(3):223-7. PubMed ID: 16794433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.